Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: enzyme inhibitors - Lixte Biotechnology Holdings

Next Previous
Drug Profile

Research programme: enzyme inhibitors - Lixte Biotechnology Holdings

Alternative Names: Cancer therapeutics - Lixte; LB-1.2; LB-102; LB-2.1; LB-200 series - Lixte; LB-201; LB-205; LB-300 series - Lixte; LB-400 series - Lixte; Neurological therapeutics - Lixte

Latest Information Update: 28 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lixte Biotechnology Holdings
  • Developer Lixte Biotechnology Holdings; National Institute of Neurological Disorders and Stroke; National Institutes of Health (USA)
  • Class Antineoplastics; Cycloheptanes; Neuroprotectants; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors; Phosphoprotein phosphatase inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Gaucher's disease; Mycoses; Neurological disorders

Most Recent Events

  • 28 Dec 2021 No recent reports of development identified for preclinical development in Cancer in USA
  • 09 Feb 2018 LB 102 is still in preclinical studies for Cancer in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top